Gabriel Allen, Maxwell G Patrick, O'Rorke Erin, Harper John R
Aesthet Surg J. 2024 Dec 12;45(1):56-62. doi: 10.1093/asj/sjae175.
Human acellular dermal matrices (ADMs) remain the most used matrices in prosthetic breast reconstruction. However, the availability and cost of ADMs limit their use in prepectoral reconstruction-which requires large amounts of ADM-and alternative matrices are therefore being explored.
The aim of this study was to demonstrate the safety and efficacy of human-porcine ADM constructs via clinical outcomes and histologic evidence of graft integration.
Consecutive patients undergoing tissue-expander/implant reconstructions with human-porcine ADM constructs were included. Biopsies of both ADMs were obtained at expander/implant exchange and evaluated for cellularization, vascularization, and inflammation. Postoperative complications were retrieved from patient records.
Fifty-nine patients met the inclusion criteria. Mean [standard deviation] follow-up was 6.7 [0.56] years; minimum follow-up was 5 years. Any complication rate was 8.6%, including skin necrosis (6.9%), seroma (1.7%), expander/implant exposure (1.7%), and return to the operating room (2.6%). A total of 138 ADM biopsy specimens were obtained from 38 patients at expander/implant exchange. Histologic analyses revealed lower fibroblast infiltration and vascularization and higher inflammatory response in porcine vs human ADM specimens, consistent with published results in nonhuman primates. Despite these differences, there were no cases of graft rejection, capsular contracture, or expander/implant loss.
Porcine ADM performs clinically in a similar manner to human ADM, albeit with minor differences in cellular ingrowth and vascularization, suggesting that it may be an alternative to human ADM in prepectoral breast reconstruction.
人脱细胞真皮基质(ADM)仍是假体乳房重建中使用最广泛的基质。然而,ADM的可用性和成本限制了其在胸肌前重建中的应用(胸肌前重建需要大量ADM),因此人们正在探索替代基质。
本研究旨在通过临床结果和移植物整合的组织学证据来证明人猪ADM构建体的安全性和有效性。
纳入连续接受人猪ADM构建体组织扩张器/植入物重建的患者。在扩张器/植入物更换时获取两种ADM的活检样本,并评估其细胞化、血管化和炎症情况。从患者记录中检索术后并发症。
59例患者符合纳入标准。平均[标准差]随访时间为6.7[0.56]年;最短随访时间为5年。任何并发症发生率为8.6%,包括皮肤坏死(6.9%)、血清肿(1.7%)、扩张器/植入物外露(1.7%)和返回手术室(2.6%)。在扩张器/植入物更换时,共从38例患者中获取了138份ADM活检标本。组织学分析显示,与人类ADM标本相比,猪ADM标本中的成纤维细胞浸润和血管化程度较低,炎症反应较高,这与在非人类灵长类动物中发表的结果一致。尽管存在这些差异,但没有发生移植物排斥、包膜挛缩或扩张器/植入物丢失的情况。
猪ADM在临床上的表现与人类ADM相似,尽管在细胞长入和血管化方面存在细微差异,这表明它可能是胸肌前乳房重建中人类ADM的替代品。